Recombinant Drugs Too Complex For 505(b)(2), Should Go To CBER – Amgen
Executive Summary
Using the 505(b)(2) application pathway to approve generic recombinant drug products could lead to an "unlawful regulatory imbalance," Amgen said
You may also be interested in...
Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich
Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich
Pfizer, Pharmacia Protest Inclusion Of Drug Innovator Data In "Paper NDAs"
Pfizer and Pharmacia are requesting that FDA revise a draft guidance so that "paper NDAs" approved under section 505(b)(2) of the Waxman/Hatch patent law would not be allowed to rely on non-published studies conducted by the product innovator.